CoChat

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma

Open access
Rapoport, Aaron P., Aqui, Nicole A., Stadtmauer, Edward A., Vogl, Dan T., Fang, Hong-Bin, Cai, Ling, Janofsky, Stephen, Chew, Anne, Storek, Jan, Akpek, Gorgun, Badros, Ashraf, Yanovich, Saul, Tan, Ming T., Veloso, Elizabeth, Pasetti, Marcela F., Cross, Alan, Philip, Sunita, Murphy, Heather, Bhagat, Rita, Zheng, Zhaohui, Milliron, Todd, Cotte, Julio, Cannon, Andrea, Levine, Bruce L., Vonderheide, Robert H., June, Carl H. · 2011 · Blood
Cited by 163

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

In a phase 1/2 two-arm trial, 54 patients with myeloma received autografts followed by ex vivo anti-CD3/anti-CD28 costimulated autologous T cells at day 2 after transplantation. Study patients positive for human leukocyte antigen A2 (arm A, n = 28) also received pneumococcal conjugate vaccine immunizations before and after transplantation and a multipeptide tumor antigen vaccine derived from the human telomerase reverse transcriptase and the antiapoptotic protein survivin. Patients negative for human leukocyte antigen A2 (arm B, n = 26) received the pneumococcal conjugate vaccine only. Patients exhibited robust T-cell recoveries by day 14 with supraphysiologic T-cell counts accompanied by a sustained reduction in regulatory T cells. The median event-free survival (EFS) for all patients is 20 months (95% confidence interval, 14.6-24.7 months); the projected 3-year overall survival is 83%. A subset of patients in arm A (36%) developed immune responses to the tumor antigen vaccine by tetramer assays, but this cohort did not exhibit better EFS. Higher posttransplantation CD4+ T-cell counts and a lower percentage of FOXP3+ T cells were associated with improved EFS. Patients exhibited accelerated polyclonal immunoglobulin recovery compared with patients without T-cell transfers. Adoptive transfer of tumor antigen vaccine-primed and costimulated T cells leads to augmented and accelerated cellular and humoral immune reconstitution, including antitumor immunity, after autologous stem cell transplantation for myeloma. This study was registered at www.clinicaltrials.gov as NCT00499577.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-08-299396

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 163

Metadata

Authors
Rapoport, A. P., Aqui, N. A., Stadtmauer, E. A., Vogl, D. T., Fang, H.-B., Cai, L., Janofsky, S., Chew, A., Storek, J., Akpek, G., Badros, A., Yanovich, S., Tan, M. T., Veloso, E., Pasetti, M. F., Cross, A., Philip, S., Murphy, H., Bhagat, R., Zheng, Z., Milliron, T., Cotte, J., Cannon, A., Levine, B. L., Vonderheide, R. H., & June, C. H.
Venue
Blood
Published
2011-01-20
Volume
117
Issue
3
Pages
788-797
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2042662562
Cited by
163
References
2
FWCI
5.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. https://app.cochat.ai/papers/10.1182/blood-2010-08-299396
The paper
Rapoport, A. P., Aqui, N. A., Stadtmauer, E. A., Vogl, D. T., Fang, H.-B., Cai, L., Janofsky, S., Chew, A., Storek, J., Akpek, G., Badros, A., Yanovich, S., Tan, M. T., Veloso, E., Pasetti, M. F., Cross, A., Philip, S., Murphy, H., Bhagat, R., . . . June, C. H. (2011). Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. https://doi.org/10.1182/blood-2010-08-299396

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.